01 3Cabenuva
02 8Complera/Eviplera
03 10Edurant
04 5Juluca
05 5Odefsey
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 964
2019 Revenue in Millions : 861
Growth (%) : 12
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,672
2019 Revenue in Millions : 1,655
Growth (%) : 1
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 269
2019 Revenue in Millions : 406
Growth (%) : -34
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 686
2019 Revenue in Millions : 507
Growth (%) : 35
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 700
2020 Revenue in Millions : 678
Growth (%) : 4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 994
2020 Revenue in Millions : 964
Growth (%) : 3
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 258
2020 Revenue in Millions : 269
Growth (%) : -4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 1,568
2020 Revenue in Millions : 1,672
Growth (%) : -6
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 51
2020 Revenue in Millions : 0
Growth (%) : New Launch in 2021
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 200
2021 Revenue in Millions : 258
Growth (%) : -22
LOOKING FOR A SUPPLIER?
